Quarterly report pursuant to Section 13 or 15(d)

SCHEDULE OF REVENUE RECOGNITION (Details)

v3.24.2.u1
SCHEDULE OF REVENUE RECOGNITION (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Product Information [Line Items]        
Total net revenue $ 2,397,652 $ 19,738 $ 4,804,043 $ 20,659
Health Care, Patient Service [Member]        
Product Information [Line Items]        
Total net revenue [1]     4,209,955
Histology Service Fees [Member]        
Product Information [Line Items]        
Total net revenue     530,053
Health Care, Other [Member]        
Product Information [Line Items]        
Total net revenue     33,193
Department of Defense Observational Studies [Member]        
Product Information [Line Items]        
Total net revenue     6,923
Other Revenues [Member]        
Product Information [Line Items]        
Total net revenue [2]     $ 23,919 $ 20,659
[1] Patient services fees include direct billing for CyPath® Lung diagnostic test of approximately $199,000.
[2] Other revenues include pre-acquisition CyPath® Lung royalty income and laboratory services.